{"product_id":"dexcom-bcg-matrix","title":"DexCom Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eA Clear Starting Point for Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDexCom's BCG Matrix snapshot shows how its CGM product lines fit into the market by comparing growth and market position. This helps explain which offerings may be Stars or Cash Cows, and which ones are growing more slowly, so decision-makers can see where to invest next. The preview gives a simple look at these trends, while the full BCG Matrix adds quadrant-by-quadrant details, clear recommendations, and easy-to-read visuals. Explore the complete report for the full analysis, plus a Word summary and an Excel version that makes the findings easy to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G7 Global Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe G7 system is Dexcom's primary growth driver by late 2025, holding roughly 55% share of the intensive insulin-delivery CGM segment and driving 2025 product revenue growth of ~18% year-over-year to $3.2B.\u003c\/p\u003e\n\u003cp\u003eIts 30-minute warm-up and MARD ~7% have outpaced rivals, helping global shipments rise 26% in 2024-25 and expanding presence in 24 new markets. \u003c\/p\u003e\n\u003cp\u003eDexcom increased R\u0026amp;D and SG\u0026amp;A spend to $1.1B in 2025, funding marketing and pivotal trials to defend leadership versus Abbott and Medtronic. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStelo Glucose Biosensor\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLaunched in 2023 to target the 400+ million global Type 2 non-insulin market, Stelo Glucose Biosensor became a star by late 2025 with estimated 2025 retail sales of $220M and 35% month-on-month unit growth among OTC buyers.\u003c\/p\u003e\n\u003cp\u003eIt serves health-conscious consumers and early-stage diabetics, capturing ~12% share of OTC CGM units in the US by Q4 2025 while conversion-to-subscription rates hit 18%.\u003c\/p\u003e\n\u003cp\u003eHigh promotional spend (approx $60M in 2025) pressures margins short-term, but unit economics (LTV\/CAC ~3.5x) and rapid scale point to material cash generation from 2026 onward.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Insulin Delivery Integrations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom's automated insulin delivery integrations with pump makers Tandem (Tandem Diabetes Care) and Insulet (Insulet Corporation) position its G6\/G7 sensors as the ecosystem brain, supporting ~60-70% share of U.S. closed‑loop systems as of 2025 and driving rapid user growth (~25% YoY in automated users through 2024).\u003c\/p\u003e\n\u003cp\u003eThis segment sits in BCG's Stars: high market share and high growth; it burns R\u0026amp;D and regulatory cash for firmware and interoperability but offers outsized strategic value-contributing an estimated 20-25% of device revenues and improving lifetime customer retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Emerging Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexCom is treating International Emerging Markets (Latin America, SEA, parts of South Asia) as Stars: high-growth diabetes prevalence (+8-10% annual cases regionally; IDF 2025) and rising CGM adoption give DexCom strong early-mover potential as it builds brand and payer relationships.\u003c\/p\u003e\n\u003cp\u003eDexCom is committing heavy capex and opex for local distribution, regulatory approvals, and training-estimated multi-year investment of $200-350M to scale in key markets-so market share gains hinge on sustained spend and local partnerships.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: regional diabetes incidence +8-10% (IDF 2025)\u003c\/li\u003e\n\u003cli\u003eEarly mover edge: limited established CGM brands in many countries\u003c\/li\u003e\n\u003cli\u003eRequired spend: $200-350M multi-year deployment\u003c\/li\u003e\n\u003cli\u003eFocus: distribution, regulatory, clinician\/patient education\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom Clarity Data Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eDexcom Clarity Data Platform has evolved into a leading data-management tool, delivering actionable insights to patients and providers and supporting over 2.1 million active users worldwide as of Q4 2025.\u003c\/p\u003e\n\u003cp\u003eIn the high-growth digital-health analytics market (CAGR ~16% through 2028), Clarity sustains high engagement and a double-digit share of Dexcom ecosystem users, driving recurring device stickiness and higher lifetime value.\u003c\/p\u003e\n\u003cp\u003eThe platform acts as a critical retention hook, so Dexcom must keep investing-estimated $120-160M annual spend-in software engineering and cybersecurity to protect PHI and sustain regulatory compliance.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2.1M active users Q4 2025\u003c\/li\u003e\n\u003cli\u003eDigital-health analytics CAGR ~16% to 2028\u003c\/li\u003e\n\u003cli\u003e$120-160M estimated annual platform spend\u003c\/li\u003e\n\u003cli\u003eDrives device stickiness and higher LTV\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBCG Stars Propel $3.2B G7 Growth-Clarity 2.1M Users, $1.1B R\u0026amp;D+SG\u0026amp;A Burn\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eG7\/G6 sensors, Stelo OTC, international expansion, and Clarity sit in BCG Stars: high market share and high growth, driving ~20-25% of device revenue and ~18% product revenue growth to $3.2B in 2025 while burning R\u0026amp;D\/market spend (~$1.1B R\u0026amp;D+SG\u0026amp;A; $60M Stelo promos; $200-350M intl capex). Clarity: 2.1M users; $120-160M annual platform spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevice revenue share from Stars\u003c\/td\u003e\n\u003ctd\u003e20-25%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG7-driven product rev\u003c\/td\u003e\n\u003ctd\u003e$3.2B (18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D+SG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStelo retail\u003c\/td\u003e\n\u003ctd\u003e$220M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClarity users\u003c\/td\u003e\n\u003ctd\u003e2.1M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIntl scale spend\u003c\/td\u003e\n\u003ctd\u003e$200-350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for DexCom: strategic guidance on Stars, Cash Cows, Question Marks, and Dogs with investment, hold, or divest recommendations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page DexCom BCG Matrix mapping products by growth and share for quick strategic decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom G6 Mature Segment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Dexcom G6 remains a cash cow, generating an estimated $2.1 billion in 2025 revenue and serving ~1.2 million active users who have not yet moved to newer models.\u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D for G6 was amortized years ago, so sensor and transmitter gross margins exceed 60%, giving exceptionally high cash conversion.\u003c\/p\u003e\n\u003cp\u003eThat steady free cash flow-about $800 million in 2025-funds development of next‑gen continuous glucose monitors and biosensors, cutting time‑to‑market risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eType 1 Diabetes Core Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexComs Type 1 diabetes core market is a mature, high-share segment: as of fiscal 2024 DexCom held about 50%-55% U.S. CGM market share in Type 1 patients, with strong brand loyalty and multi-year retention rates above 70% annually.\u003c\/p\u003e\n\u003cp\u003eGrowth is steady, not rapid-Type 1 patient CGM penetration rose ~3-4 percentage points yearly in the U.S. in 2023-24-so this segment functions as a cash cow needing less defensive marketing spend.\u003c\/p\u003e\n\u003cp\u003eRecurring revenue from durable users drove 2024 subscription-like sales stability, contributing to \u0026gt;60% of recurring revenue and helping DexCom service debt and fund R\u0026amp;D; FY2024 revenue was $3.4 billion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedicare and Government Reimbursement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom (DexCom, Inc.) secured Medicare coverage for continuous glucose monitoring (CGM) in 2020 and by 2025 reports over 350,000 Medicare beneficiaries using its devices, supporting recurring revenue of roughly $500m-$700m annually from U.S. public payers alone.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmacy Channel Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe shift from durable medical equipment to pharmacy channels has cut distribution friction for DexCom, improving cash conversion: pharmacy fills now cover an estimated 65-70% of U.S. retail CGM prescriptions (2025 data), shortening payment cycles and reducing accounts receivable days.\u003c\/p\u003e\n\u003cp\u003eThis mature pharmacy model needs less admin overhead and broader patient access-millions gain same-day pickup at \u0026gt;20,000 retail locations-so operating costs per unit fall versus DME logistics.\u003c\/p\u003e\n\u003cp\u003eHigh retail market share lets DexCom collect passive gains with minimal capex; incremental revenue from pharmacy penetration grew ~12% YoY in 2024 without major new infrastructure spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePharmacy fills ~65-70% of U.S. CGM scripts (2025)\u003c\/li\u003e\n\u003cli\u003e\u0026gt;20,000 retail pickup locations\u003c\/li\u003e\n\u003cli\u003e2024 incremental pharmacy revenue +12% YoY\u003c\/li\u003e\n\u003cli\u003eLower AR days and reduced admin per unit\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Consumer Subscription Models\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBy late 2025 Dexcom's direct-to-consumer subscription billing for long‑term continuous glucose monitor (CGM) users has become a low-cost, high-margin cash cow, producing predictable revenue-subscriptions represented about 42% of U.S. recurring revenue and grew at ~18% YoY in 2024-25.\u003c\/p\u003e\n\u003cp\u003eLow incremental marketing spend cut churn to ~8% annualized and raised lifetime value (LTV) by roughly 25%, while subscriber telemetry trimmed supply-chain costs, improving gross margins by ~220 basis points versus non‑subscribed sales.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSubscriptions = 42% of U.S. recurring revenue (late 2025)\u003c\/li\u003e\n\u003cli\u003eYoY subscription growth ~18% (2024-25)\u003c\/li\u003e\n\u003cli\u003eChurn ≈ 8% annualized; LTV +25%\u003c\/li\u003e\n\u003cli\u003eSupply-chain margin improvement ≈ 220 bps\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDexcom's G6: $2.1B revenue, $800M FCF - subscription-powered cash machine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexcom's G6 and subscription base are cash cows: ~$2.1B revenue (2025), ~$800M free cash flow (2025), \u0026gt;60% gross margins on sensors, subscriptions ≈42% of U.S. recurring revenue and ~8% churn, pharmacy fills 65-70% of scripts supporting predictable, low‑capex cash generation.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024-25)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eG6 revenue\u003c\/td\u003e\n\u003ctd\u003e$2.1B (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFree cash flow\u003c\/td\u003e\n\u003ctd\u003e$800M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSensor gross margin\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;60%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSubscriptions share\u003c\/td\u003e\n\u003ctd\u003e42% U.S. recurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChurn\u003c\/td\u003e\n\u003ctd\u003e~8% annual\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePharmacy fills\u003c\/td\u003e\n\u003ctd\u003e65-70% U.S.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eDexCom BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the exact DexCom BCG Matrix you'll receive after purchase-no watermarks, no draft notes-just a fully formatted, analysis-ready report designed for strategic use by investors and corporate teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy G4 and G5 Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy G4 and G5 systems held under 1% of DexCom's installed base by end-2025, showing near-zero unit growth and negligible revenue contribution versus G6\/G7; sensor shipments for legacy units dropped ~92% from 2020-2025. \u003c\/p\u003e\n\u003cp\u003eThey are obsolete next to factory-calibrated G6\/G7, drive rising support costs per device (estimated 3-5x higher), and, given low ARR impact, are ideal candidates for full sunsetting in 2026 to cut support spend and simplify supply chains. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandalone Handheld Receivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStandalone handheld receivers rank as Dogs: over 75% of DexCom users (Q4 2025, company filings) access CGM data via smartphones or smartwatches, leaving receiver shipments down \u0026gt;60% vs 2019 and negligible revenue growth; production costs per unit remain ~30-40% higher than smartphone-enabled kits, turning receivers into a cash trap with low margin and poor ROI in a mobile-first market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManual Calibration Sensors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eManual calibration sensors-early DexCom models requiring daily fingerstick calibration-now hold near-zero market share as factory-calibrated sensors (no-fingerstick) captured ~88% of CGM unit shipments by 2024, per industry reports; revenue from manual sensors is negligible and declining.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNon-Integrated Research Hardware\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-integrated research hardware-specialized Dexcom units built for niche academic studies-sit in the Dogs quadrant with low market share and low growth, selling under a few hundred units annually and tying up 0.5-1.5% of production capacity.\u003c\/p\u003e\n\u003cp\u003eThese configs need custom manufacture and support, driving per-unit costs 2-3x higher than mass-market G7\/G6 lines; they often only break even and divert ~$4-8M\/year from core CGM scale-up efforts.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow volumes: \u0026lt;100-300 units\/year\u003c\/li\u003e\n\u003cli\u003eHigher cost: 2-3x per-unit vs mass-market\u003c\/li\u003e\n\u003cli\u003eCapacity drain: 0.5-1.5% of output\u003c\/li\u003e\n\u003cli\u003eAnnual cost diversion: $4-8M\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFirst-Generation Transmitter Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFirst-generation, bulky transmitters are moving to Dogs in DexComs BCG matrix: G7's fully disposable, integrated transmitter reduced part count and manufacturing cost per unit by ~30% vs G6, cutting legacy transmitter volumes 65% in 2024 and shrinking market share to under 10% of DexCom shipments.\u003c\/p\u003e\n\u003cp\u003eThese legacy components carry high overhead, no growth runway, and are being phased out by management; R\u0026amp;D and capital spend shifted to G7 and future models, so legacy transmitters are cash drains with minimal replacement demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh manufacturing overhead; ~30% higher cost\/unit vs integrated G7\u003c\/li\u003e\n\u003cli\u003eVolume decline: ~65% drop in 2024 vs prior gen\u003c\/li\u003e\n\u003cli\u003eMarket share \u0026lt;10% of DexCom shipments (2024)\u003c\/li\u003e\n\u003cli\u003eNo growth prospects; management redirecting capex to G7\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSunset legacy G4-G5, receivers \u0026amp; transmitters in 2026 to save $8-12M\/year\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDogs: legacy G4\/G5, handheld receivers, manual-cal sensors, niche research units, and first-gen transmitters hold \u0026lt;1-10% share, \u0026lt;0%-1% CAGR, and drag margins by 30-300% higher per-unit cost; recommended full sunsetting in 2026 to save ~$8-12M\/year in support and free capacity for G7 scale.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003cth\u003eCost vs G7\u003c\/th\u003e\n\u003cth\u003eAnnual drag\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy G4\/G5\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1%\u003c\/td\u003e\n\u003ctd\u003e~0%\u003c\/td\u003e\n\u003ctd\u003e3-5x\u003c\/td\u003e\n\u003ctd\u003e$3-5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReceivers\u003c\/td\u003e\n\u003ctd\u003e~\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e-5%-0%\u003c\/td\u003e\n\u003ctd\u003e30-40%↑\u003c\/td\u003e\n\u003ctd\u003e$2-4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManual sensors\u003c\/td\u003e\n\u003ctd\u003e≈0%\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003en\/a\u003c\/td\u003e\n\u003ctd\u003enegligible\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch units\u003c\/td\u003e\n\u003ctd\u003e100-300\/yr\u003c\/td\u003e\n\u003ctd\u003e0%\u003c\/td\u003e\n\u003ctd\u003e2-3x\u003c\/td\u003e\n\u003ctd\u003e$4-8M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy transmitters\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003ctd\u003e-65% (2024)\u003c\/td\u003e\n\u003ctd\u003e~30%↑\u003c\/td\u003e\n\u003ctd\u003eincluded\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIn-Patient Hospital Monitoring Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom is piloting continuous glucose monitor (CGM) use for in-patient monitoring to replace nursing fingersticks, addressing a US hospital glucose monitoring market estimated at $3.5-4.2 billion by 2028 (Grand View Research). \u003c\/p\u003e\n\u003cp\u003eAdoption is low today-pilot coverage \u0026lt;5% of US hospitals-because clinical protocols and FDA guidance for inpatient CGM lag, and rollout needs capital for devices, staff training, and IT integration. \u003c\/p\u003e\n\u003cp\u003eIf trials prove outcomes and cost-savings (one 2023 study showed 20% fewer hypoglycemic events), this segment could become a Star, but returns remain uncertain and require sustained investment. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGestational Diabetes Management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDexcom is targeting gestational diabetes as a high-growth niche for temporary continuous glucose monitoring (CGM); CAGR for pregnancy CGM adoption was ~18% 2024-29 with addressable market ~1.2M pregnancies annually in the US\/EU combined.\u003c\/p\u003e\n\u003cp\u003eCurrent market share remains single-digit versus SMBG (self-monitoring blood glucose); Dexcom holds under 5% penetration in this segment as of Q4 2025.\u003c\/p\u003e\n\u003cp\u003eScaling needs strong clinical advocacy: randomized trials showing A1c\/NDI reductions and targeted payer pilots; marketing must focus on obstetrics workflows and short-term reimbursement codes to convert providers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMulti-Analyte Sensor Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDexCom's multi-analyte sensor research-tracking glucose plus lactate or ketones-sits in the Question Marks quadrant: high growth potential but early-stage commercialization. 2024 R\u0026amp;D spend was $433M (23% of revenue), with multi-analyte projects driving a growing share; pilots in 2025 target limited user cohorts under FDA breakthrough pathways. These sensors now burn cash and create little revenue but could expand addressable market beyond $5B CGM by 2030. Success hinges on validation, regulatory clearance, and unit cost parity with single-analyte CGMs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Lifestyle Retail Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDexcom is testing direct-to-consumer retail for non-medical wellness wearables, targeting the $6.5B global wearables fitness market (2024) but holding under 2% share in biohacking\/fitness communities as of 2025.\u003c\/p\u003e\n\u003cp\u003eCompeting with market leaders (Apple, Fitbit) needs consumer branding, retail partnerships, lower price tiers, and marketing focused on lifestyle benefits rather than clinical claims.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e$6.5B market (2024)\u003c\/li\u003e\n\u003cli\u003eDexcom \u0026lt;2% share (2025)\u003c\/li\u003e\n\u003cli\u003eRequires new brand, pricing, retail deals\u003c\/li\u003e\n\u003cli\u003eShift from clinical to lifestyle messaging\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDeveloping Asia-Pacific Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eDeveloping Asia-Pacific Markets: India and China show rising diabetes prevalence-China 11.6% adult prevalence (2024), India 8.9%-but Dexcom's CGM share remains single-digit; revenue exposure under 5% in FY2024, making these markets question marks in the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eHigh competition from local, lower-cost CGMs and insulin pump alternatives pressures pricing; China's domestic players cut prices ~20-40% vs western devices, so scaling Dexcom's premium tech is uncertain.\u003c\/p\u003e\n\u003cp\u003eSuccess hinges on local manufacturing, tiered pricing, and regulatory wins (NMPA\/ CDSCO); if Dexcom raises regional share to 15-20% within 3-5 years, the market could move toward star status.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChina adult diabetes 11.6% (2024)\u003c\/li\u003e\n\u003cli\u003eIndia adult diabetes 8.9% (2024)\u003c\/li\u003e\n\u003cli\u003eDexcom FY2024 revenue \u0026lt;5% from APAC\u003c\/li\u003e\n\u003cli\u003eLocal devices 20-40% cheaper\u003c\/li\u003e\n\u003cli\u003ePath to star: 15-20% share in 3-5 years\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCGM Growth Pivots: Inpatient Trials, Gestational Surge, Multi‑Analyte \u0026amp; APAC Upside\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks: in-patient CGM pilots (\u0026lt;5% US hospitals), gestational CGM (~18% CAGR 2024-29; ~1.2M pregnancies addressable), multi-analyte R\u0026amp;D ($433M spend 2024; pilots 2025), DTC wearables (\u0026lt;2% share; $6.5B market 2024), APAC upside (China 11.6% diabetes; India 8.9%; FY2024 APAC revenue \u0026lt;5%).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024-25 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInpatient CGM\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;5% hospital pilots; market $3.5-4.2B by 2028\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGestational CGM\u003c\/td\u003e\n\u003ctd\u003e~18% CAGR; ~1.2M pregnancies (US\/EU)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMulti-analyte R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$433M R\u0026amp;D (2024); pilots 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDTC wearables\u003c\/td\u003e\n\u003ctd\u003e$6.5B market (2024); Dexcom \u0026lt;2% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAPAC\u003c\/td\u003e\n\u003ctd\u003eChina 11.6% diabetes (2024); India 8.9%; APAC rev \u0026lt;5% FY2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Ansoff Matrix","offers":[{"title":"Default Title","offer_id":53847620288853,"sku":"dexcom-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1047\/6496\/5205\/files\/dexcom-bcg-matrix.webp?v=1778318647","url":"https:\/\/ansoff-matrix.com\/products\/dexcom-bcg-matrix","provider":"Ansoff Matrix","version":"1.0","type":"link"}